Diet pills are tablets that are used in conjunction with a good diet and exercise routine to help people lose weight. There are a variety of options, but the NHS considers most of them ineffective. Some diet pills may be useless in helping people lose weight, while others may be effective yet too dangerous to use. Phentermine and topiramate-containing weight loss tablets have been proved to help people lose weight.
Novo Nordisk and F. Hoffmann-La Roche AG- Notable Market Players in Diet Pills Market
The Diet Pills market majorly consists of the players such as Novo Nordisk A/S, Gelesis, VIVUS LLC, Chong’s Health Care, GlaxoSmithKline plc., Pfizer Inc. (Arena Pharmaceutical GmbH), Iovate Health Sciences International Inc., Zoller Laboratories, Currax Pharmaceuticals LLC., TEVA PHARMACEUTICAL INDUSTRIES LTD. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the Diet Pills market:
| Year | News |
| Jun-21 | Novo Nordisk A/S received US Food and Drug Administration (FDA) approval for Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. The approval was based on the results from the STEP phase 3a clinical trial programme. |
| Feb’21 | Iovate Health Sciences International Inc. under its nationally recognized Hydroxycut weight loss supplement brand announced the launch of a new National U.S. brand campaign, “No Fads. Just Weight Loss. The campaign aims to highlight a three-step weight-loss journey. |
| Dec-20 | Novo Nordisk A/S received US Food and Drug Administration (FDA) approval for Saxenda (liraglutide) injection 3 mg for the treatment of obesity in adolescents aged 12-17 with a body weight above 60 kg and an initial body mass index (BMI) corresponding to 30 kg/m2 or greater for adults, as an adjunct to reduced-calorie meals and increased physical activity. |
| Feb’20 | VIVUS LLC, Korean marketing partner, Alvogen, launched Qsymia (phentermine and topiramate extended-release) in the Republic of Korea. VIVUS LLC entered into an agreement with an established leader in the South Korean anti-obesity market, Alvogen to maximize the value of our commercial-stage assets in an efficient and cost-effective manner. |
| Feb’20 | TEVA PHARMACEUTICAL INDUSTRIES LTD ceased the distribution of weight loss drug Belviq in Israel amid cancer scare. The company filed a voluntary request to withdraw the drug following a request from the FDA, due to clinical trial findings that showed the drug might increase risk of cancer.. Furthermore, company started recalling the drug in collaboration with the Israeli Ministry of Health. |
| Oct-20 | The U.K.’s National Institute for Health and Care Excellence recommended Novo Nordisk A/S’ diabetes drug liraglutide marketed as Saxenda in the U.K for treating high blood sugar in non-diabetic patients with obesity. NICE’s draft guidance advises healthcare professionals to discontinue treatment if at least 5% of a patient’s body weight has not been lost after 12 weeks on the full dose. It also advises treatment for all patients be stopped after two years. |
| Apr-19 | Gelesis received FDA Clearance to market PLENITY as an aid to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract. PLENITY represents a new prescription option for millions of adults. |
| Dec-21 | Pfizer Inc. acquired Arena Pharmaceuticals for about USD 6.7 billion to reshape itself around a portfolio of inflammation drugs.. Furthermore, Pfizer was uniquely positioned to acquire more assets as well. |
| Sep’19 | Currax Pharmaceuticals LLC acquired Nalpropion Pharmaceuticals, Inc. As a result of this acquisition, Currax owned the world-wide rights to CONTRAVE, which is the number one prescribed weight-loss brand medication in the United States. |
